Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 20,092	$ 22,895
Accounts receivable, net	1,804	302
Receivable from Sanofi		30,557
Inventory	3,129	2,331
Asset held for sale		16,730
Deferred costs from commercial product sales	543	309
Prepaid expenses and other current assets	3,061	4,364
Total current assets	28,629	77,488
Property and equipment - net	27,374	28,927
Other assets	480	648
Total assets	56,483	107,063
Current liabilities:
Accounts payable	5,283	3,263
Accrued expenses and other current liabilities	12,492	7,937
Facility financing obligation	57,942	71,339
Deferred revenue - net	3,021	3,419
Deferred payments from collaboration - current	250	1,000
Recognized loss on purchase commitments - current	12,480	5,093
Total current liabilities	91,468	92,051
Note payable to principal stockholder	79,666	49,521
Accrued interest - note payable to principal stockholder	1,173	9,281
Senior convertible notes	27,657	27,635
Recognized loss on purchase commitments - long term	99,769	95,942
Deferred payments from collaboration - long term	563
Warrant liability		7,381
Milestone rights liability and other liabilities	7,202	8,845
Total liabilities	307,498	290,656
Commitments and contingencies (Note 11)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016
Common stock, $0.01 par value - 140,000,000 shares authorized, 104,707,116 and 95,680,831 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	1,047	957
Additional paid-in capital	2,570,072	2,553,039
Accumulated other comprehensive loss	(20)	(24)
Accumulated deficit	(2,822,114)	(2,737,565)
Total stockholders' deficit	(251,015)	(183,593)
Total liabilities and stockholders' deficit	$ 56,483	$ 107,063